Discovery of a potential biomarker for immunotherapy of melanoma: PLAC1 as an emerging target

References

• Eisenstein A, Gonzalez EC, Raghunathan R, et al. Emerging biomarkers in cutaneous melanoma. Mol Diagn Ther. 2018;22:203–218.
   PubMed Web of Science ®Google Scholar
• Najem A, Krayem M, Perdrix A, et al. New drug combination strategies in melanoma: current status and future directions. Anticancer Res. 2017;37:5941–5953.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13:1020–1024.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71:161–169.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193–3198.
   PubMed Web of Science ®Google Scholar
• Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol. 2011;65:S78–S86.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10:588–598.
   PubMed Web of Science ®Google Scholar
• Okuyama S, Gonzalez R, Lewis KD. Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. Core Evid. 2010;5:39–48.
   PubMedGoogle Scholar
• Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2:336–352.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Gogas H, Kirkwood JM. IFN-α in the treatment of melanoma . J Immunol. 2012;189:3789–3793.
   PubMed Web of Science ®Google Scholar
• Herndon TM, Demko SG, Jiang X, et al. U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist. 2012;17:1323–1328.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–482.
   PubMed Web of Science ®Google Scholar
• Munhoz RR, Postow MA. Clinical development of PD-1/PD-L1 in advanced melanoma. Cancer J. 2018;24:7.
   PubMed Web of Science ®Google Scholar
• Kwiatkowska D, Kluska P, Reich A. Beyond PD-1 immunotherapy in malignant melanoma. Dermatol Ther (Heidelb). 2019;9:243–257.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Rotte A, Bhandaru M, Zhou Y, et al. Immunotherapy of melanoma: present options and future promises. Cancer Metastasis Rev. 2015;34:115–128.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Curr Treat Options Oncol. 2002;3:193–203.
   PubMedGoogle Scholar
• Brougham ND, Dennett ER, Tan ST. Non-melanoma skin cancers in New Zealand–a neglected problem. N Z Med J. 2010;123:59–65.
   PubMedGoogle Scholar
• Ghods R, Ghahremani MH, Madjd Z, et al. High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. Cancer Immunol Immunother. 2014;63:1319–1327.
   PubMed Web of Science ®Google Scholar
• Nejadmoghaddam MR, Zarnani AH, Ghahremanzadeh R, et al. Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy. Sci Rep. 2017;7:13373.
   PubMed Web of Science ®Google Scholar
• Cocchia M, Huber R, Pantano S, et al. PLAC1, an Xq26 gene with placenta-specific expression. Genomics. 2000;68:305–312.
   PubMed Web of Science ®Google Scholar
• Fant M, Farina A, Nagaraja R, et al. PLAC1 (Placenta-specific 1): a novel, X-linked gene with roles in reproductive and cancer biology. Prenat Diagn. 2010;30:497–502.
   PubMed Web of Science ®Google Scholar
• Silva WA, Jr., Gnjatic S, Ritter E, et al. PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun. 2007;7:18.
   Google Scholar
• Fant M, Weisoly DL, Cocchia M, et al. PLAC1, a trophoblast-specific gene, is expressed throughout pregnancy in the human placenta and modulated by keratinocyte growth factor. Mol Reprod Dev. 2002;63:430–436.
   PubMed Web of Science ®Google Scholar
• Massabbal E, Parveen S, Weisoly DL, et al. PLAC1 expression increases during trophoblast differentiation: evidence for regulatory interactions with the fibroblast growth factor-7 (FGF-7) axis. Mol Reprod Dev. 2005;71:299–304.
   PubMed Web of Science ®Google Scholar
• Mahmoudian J, Ghods R, Nazari M, et al. PLAC1: biology and potential application in cancer immunotherapy. Cancer Immunol Immunother. 2019;68:1039–1020.
   PubMed Web of Science ®Google Scholar
• Jackman SM, Kong X, Fant ME. Plac1 (placenta-specific 1) is essential for normal placental and embryonic developmentMolecular. Mol Reprod Dev. 2012;79:564–572.
   PubMed Web of Science ®Google Scholar
• Koslowski M, Sahin U, Mitnacht-Kraus R, et al. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res. 2007;67:9528–9534.
   PubMed Web of Science ®Google Scholar
• Chen J, Pang XW, Liu FF, et al. PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients [English Abstract]. Beijing Da Xue Xue Bao. 2006;38:124–127.
   PubMedGoogle Scholar
• Dong XY, Peng JR, Ye YJ, et al. Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patientsInternational. Int J Cancer. 2008;122:2038–2043.
   PubMed Web of Science ®Google Scholar
• Tchabo NE, Mhawech-Fauceglia P, Caballero OL, et al. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun. 2009;9:6.
   PubMedGoogle Scholar
• Mahmoudian J, Ghods R, Nazari M, et al. Expression profiling of plac1 in murine cancer cell lines. Exp Oncol. 2019;41:7–13.
   PubMedGoogle Scholar
• Ghods R, Ghahremani MH, Darzi M, et al. Immunohistochemical characterization of novel murine monoclonal antibodies against human PLAC1. Biotechnol Appl Biochem. 2014;61:363–369.
   PubMed Web of Science ®Google Scholar
• Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51–65.
   PubMed Web of Science ®Google Scholar
• Pitcovski J, Shahar E, Aizenshtein E, et al. Melanoma antigens and related immunological markers. Crit Rev Oncol Hematol. 2017;115:36–49.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lin X, Di X, et al. Oncogenic function of Plac1 on the proliferation and metastasis in hepatocellular carcinoma cells. Oncol Rep. 2017;37:465–473.
   PubMed Web of Science ®Google Scholar
• Li Y, Chu J, Li J, et al. Cancer/testis antigen-Plac1 promotes invasion and metastasis of breast cancer through Furin/NICD/PTEN signaling pathway. Mol Oncol. 2018;12:1233–1248.
   PubMed Web of Science ®Google Scholar
• Yang L, Zha TQ, He X, et al. Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer. Oncol Rep. 2018;39:53–60.
   PubMed Web of Science ®Google Scholar
• Shantha Kumara H, Grieco MJ, Caballero OL, et al. MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immunity. 2012;12:16.
   PubMedGoogle Scholar
• Liu F, Shen D, Kang X, et al. New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma. J Clin Pathol. 2015;68:913–916.
   PubMed Web of Science ®Google Scholar
• Devor EJ, Leslie KK. The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines. Obstet Gynecol Int. 2013;2013:807849.
   PubMedGoogle Scholar
• Yin Y, Zhu X, Huang S, et al. Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma. Tumour Biol. 2017;39:101042831769913.
   Google Scholar
• Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–5337.
   PubMed Web of Science ®Google Scholar
• Lopes-Ramos CM, Paulson JN, Chen CY, et al. Regulatory network changes between cell lines and their tissues of origin. BMC Genomics. 2017;18:723.
   PubMed Web of Science ®Google Scholar
• Jiang G, Zhang S, Yazdanparast A, et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016;17 Suppl 7:525.
   PubMed Web of Science ®Google Scholar
• Sandberg R, Ernberg I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci U S A. 2005;102:2052–2057.
   PubMed Web of Science ®Google Scholar
• Zarnani AH, Bozorgmehr M, Shabani M, et al. Monoclonal antibodies for cancer immunotherapy. In: Rezaei N, editor. Cancer immunology. Cham (Switzerland): Springer; 2015. p. 293–328.
   Google Scholar